Clinical Trials Browser

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

NCT00330759 2022-11-07

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Phase 3 Completed

1,779 enrolled 14 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Spinal Cord Compression

NCT00680992 2022-09-22

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Phase 2 Completed

535 enrolled 16 charts

Giant Cell Tumors, Neoplasms, Giant Cell Tumor of Bone

NCT03382574 2022-06-14

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Phase EARLY_PHASE1 Terminated

2 enrolled

Gynecologic

Ovarian Neoplasms

NCT03161756 2022-04-07

CHARLI

Phase 1/2 Unknown

72 enrolled

Dermatologic

Melanoma

NCT03732495 2022-03-29

LENVOS

Phase 2 Unknown

35 enrolled

EndocrineHead & Neck

Thyroid Cancer Metastatic

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2 Completed

6 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT03691311 2021-11-03

D-BIOMARK

Phase EARLY_PHASE1 Unknown

60 enrolled

Breast

Osteopetrosis, mild autosomal recessive form, Osteopetrosis, Autosomal Recessive 7, Breast Neoplasms

NCT01951586 2021-10-25

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

226 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03408652 2021-10-22

MOSCAR

Phase 3 Terminated

1 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT02366130 2021-10-07

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Phase 2 Completed

45 enrolled 7 charts

Breast

Breast Neoplasms

NCT01077154 2021-09-28

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Phase 3 Terminated

4,509 enrolled 25 charts

Breast

Breast Neoplasms

NCT04859569 2021-06-07

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Phase 3 Unknown

850 enrolled

Other solid neoplasm

Bone Metastases From Solid Tumors

NCT03027557 2021-05-25

DENOCINA

Phase 3 Completed

46 enrolled 49 charts

Head & Neck

Parathyroid Neoplasms, Hyperparathyroidism, Primary

NCT04798326 2021-03-15

MW032

Phase 1 Completed

120 enrolled

Sarcoma

Bone Neoplasms

NCT01624766 2021-02-25

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

Phase 1 Completed

57 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT02682693 2021-02-02

GeparX

Phase 2 Completed

780 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT03620149 2021-01-06

REDUCE

Phase 2 Terminated

2 enrolled

Giant Cell Tumor of Bone

NCT02721433 2020-12-02

REaCT-BTA

Phase 4 Completed

263 enrolled

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

Clinical Trials

ZAMBONI

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Denosumab Strategy for Liver Cancer With Bone Metastases

DICE

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

DenosuMast

TRIDENT

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

Denosumab for Smoldering Multiple Myeloma

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

ETC-159-02

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

BRCA-P

KEYNOTE-E86

DEFENCE

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

RANKL Inhibition and Breast Tissue Biomarkers

SPLENDOUR

Dmab

Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

KEYPAD

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

CHARLI

LENVOS

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

D-BIOMARK

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

MOSCAR

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

DENOCINA

MW032

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

GeparX

REDUCE

REaCT-BTA